NOX 200

Drug Profile

NOX 200

Latest Information Update: 16 Aug 2002

Price : $50

At a glance

  • Originator Medinox
  • Class Antihyperglycaemics; Antirheumatics; Small molecules
  • Mechanism of Action Nitric oxide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Rheumatoid arthritis; Type 1 diabetes mellitus

Most Recent Events

  • 19 Oct 1998 New profile
  • 19 Oct 1998 Preclinical development for Rheumatoid arthritis in USA (PO)
  • 19 Oct 1998 Preclinical development for Type-1 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top